RxDoctor Payments Data

Margarita Symonian Silver, MD

Nephrology · Los Angeles, CANPI 1528140696

Payments from drug & device makers

$1,914in general payments, 2019–2025

Across 83 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$702
  • Fresenius USA Marketing, Inc.$250
  • Ardelyx, Inc.$242
  • AstraZeneca$180
  • AbbVie$125
  • Sanofi$121
  • plus $294 from 6 others

What the payments were for

  • Food & beverage$1,79194%
  • Education$1236%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,914 in reported general payments places this provider in the 55th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$170,573
Medicare patients
80
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RenvelaSevelamer Carbonate11$20,018
Sevelamer Hcl13$13,617
JanuviaSitagliptin Phosphate18$13,182
ProcritEpoetin Alfa20$10,304
Sevelamer Carbonate37$9,787
LokelmaSodium Zirconium Cyclosilicate22$9,735
JardianceEmpagliflozin17$9,600
TradjentaLinagliptin19$8,707
AuryxiaFerric Citrate12$8,305
DiovanValsartan13$7,554
VascepaIcosapent Ethyl19$6,348
FarxigaDapagliflozin Propanediol12$6,080
Febuxostat41$5,145
TegretolCarbamazepine13$4,573
Dexlansoprazole DrDexlansoprazole18$3,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga, Nexium$180$18,63545 claims
Akebia Therapeutics IncAuryxia$702$8,30512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,341 nephrology providers in California.

Other nephrology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →